← IPO Calendar

ADARx Pharmaceuticals, Inc.

ADRX
priced
Analyst-verified

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The company is advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx aims to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

Exchange
Nasdaq
Analyst-verified
Price
$17.00
Source: Finnhub
Shares offered
26,250,000
Source: Finnhub
Expected date
2026-09-25
Source: Finnhub
Priced date
2026-09-25
Source: Finnhub
Industry
Biotechnology
AI-extracted
Revenue
—
Net income
—
Underwriters

Not yet disclosed.

Filings

Track ADRX

Get alerts on new filings and ask our AI analyst about this company.

Research this company
ADARx Pharmaceuticals, Inc. (ADRX) IPO | PublicView